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LETTER TO THE EDITOR
Readers are encouraged to write letters to the editor concerning articles that have been published in Clinical Gastroenterology
and Hepatology. Short, general comments are also considered, but use of the Letters to the Editor section for publication of
original data in preliminary form is not encouraged. Letters should be typewritten and submitted electronically to http://www.
editorialmanager.com/cgh.

Increased Diagnosis of Hepatocellular
Carcinoma in Hospitalized Patients with
Alcohol Related Hepatitis after the Covid19 Outbreak: A Global Multi-Center
Propensity Matched Analysis
We have read the recent article by Kim et al1 with
interest. We extended our study into the course of
hepatocellular carcinoma (HCC) in patients with alcoholrelated hepatitis post COVID-19 pandemic. The Coronavirus 2019 (COVID-19) pandemic has posed signiﬁcant
challenges in the management of chronic liver disease.
Missed or delayed diagnosis of HCC is anticipated due to
temporary interruption in standard surveillance protocols during the pandemic, although no large studies
have documented these results. We attempted to study
the baseline characteristics and outcomes in patients
hospitalized with alcohol-related hepatitis, before and
after the COVID-19 outbreak, and analyze the impact on
outcomes including the diagnosis of HCC and inpatient
mortality. A federated cloud-based network (TriNetX)
data from ﬁfty health care organizations across the globe
was analyzed retrospectively.2 Patients admitted with
alcohol-related hepatitis between January 2019 and
December 2020 were studied. They were categorized
into 2 groups including post-COVID outbreak (group 1,
January 1, 2020 to December 1, 2020) and pre-COVID
outbreak (group 2, January 1, 2019 to December 1,
2019). Patient characteristics and outcomes related to
hospitalization were compared between these groups.
Of 23,201 patients studied, 4383 patients were
included in post-COVID, and 18,818 pre-COVID group.
The 2 groups had comparable demographic features and
occurrence of other comorbid diseases (Table 1), none of
which had a COVID-19 diagnosis. After propensity
matched analysis, we found that post-COVID group had a
tendency to have higher total bilirubin levels (P ¼ .05)
during hospitalization. Similarly, the post-COVID group
had a higher proportion of patients with underlying
cirrhosis (P ¼ 0.02). Patients had a similar course during
hospitalization including most of the variables compared
among the 2 groups except the occurrence of hepatorenal syndrome (higher in the post-COVID group;

P < .001). Among the outcome variables studied, the
post-COVID group had an increased occurrence of HCC
(odds ratio [OR], 1.19; 95% conﬁdence interval [CI],
1.08–1.32; P < .001), however occurrence of ascites (OR,
0.72; 95% CI, 0.45–1.17; P ¼ .18), hepatic encephalopathy (OR, 0.74; CI, 0.49–1.11; P ¼ .15), need for steroid
use (OR, 1.13; CI, 0.91–1.41; P ¼ .24) and inpatient death
(OR, 0.93; CI, 0.72–1.20; P ¼ .59) were comparable
among both groups.
These results might indicate decreased outpatient
diagnosis of HCC, likely from delay or discontinuity in
standard HCC surveillance as a result of the COVID-19
outbreak. We may infer that higher bilirubin levels and
higher diagnosis of cirrhosis in the post-COVID group are
consequent to general patient behavior of seeking medical care only with increased symptoms during the
pandemic, however this did not translate to increased
mortality. HCC is a slow growing tumor with a tumor
doubling time of 6 months and we anticipate that the
clinical impact of a missed diagnosis will be more
remarkable in long term follow up in the post pandemic
phase, and our results probably indicate only the tip of
an iceberg. A larger study including the hospitalized and
outpatient population might address this issue more
appropriately. Tapper et al described 3 waves of the
impact of COVID-19 on cirrhosis care; (1) an early high
acuity phase with delayed routine care, (2) a challenging
‘return to normal’ phase, and (3) a ﬁnal phase of missed
diagnoses and progressive disease.1 Our study testiﬁes
these predictions, and we recommend a greater caution
as we encounter patients at risk for HCC in clinics, to
conﬁrm that they have not missed their scheduled ultrasound surveillance.
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Table 1. Propensity Matched Comparison of Groups With Alcohol-Related Hepatitis After and Before COVID-19 Outbreak
After matching

Before matching

P valuea

Post-COVID
(group 1)
n ¼ 4383

Pre-COVID
(group 2)
n ¼ 4383

P value

50.2  12.3

.01

49.7  12.3

49.7  12.2

.09

63.9

64.7

.33

63.9

63.7

.82

28.1  5.9

27.7  5.8

.02

28.2  5.9

27.7  5.8

.09

Hypertension

65.5

65.6

.89

66.5

66.6

.26

Diabetes mellitus

21.5

22.5

.14

21.5

20.9

.56

Obesity

27.3

23.9

< .001

27.3

26.7

.58

Age, y ( SD)

Post-COVID
(group 1)
n ¼ 4383

Pre-COVID
(group 2)
n ¼ 18,818

49.7  12.3

Gender, male, %
2

BMI, kg/m ( SD)
Comorbid diseases, %

Chronic kidney disease

11.1

10.5

.25

11.1

9.9

.08

Coronary artery disease

18.1

18.3

.75

18.1

17.8

.73

COPD

18.9

20.3

.39

18.9

18.7

.80

Cerebrovascular disease

11.0

12.7

.003

11.0

10.8

.68

HbA1c ( SD)

6.3  2.3

6.3  2.2

.71

6.3  2.3

6.2  1.9

.89

Hemoglobin, g/dL ( SD)

13.1  2.1

11.4  2.6

.01

214.5  123.2

214.2  100.8

.96

214.5  123.2

213.7  104.2

.94

Serum sodium, mEq/dL ( SD)

138.4  3.6

138.5  3.8

.66

138.4  3.6

138.4  4.1

.54

Creatinine, mg/dL ( SD)

2.08  10.1

1.98  10.5

.89

2.08  10.1

1.2  4.4

.33

1.4  2.9

1.5  3.8

.72

0.71  0.3

1.4  2.9

.05

Laboratory values

Platelet count, per mL ( SD)

Bilirubin, total, mg/dL ( SD)

a

Alanine transaminase, U/L ( SD)

56.5  53.0

57.8  101.5

.86

56.5  53.0

54.5  56.0

.72

Aspartate transaminase, U/L ( SD)

77.2  81.3

82.4  207.6

.74

66.5  69.5

82.3  207.6

.21

Albumin, g/dL ( SD)

3.8  0.8

3.9  0.8

.29

3.8  0.8

3.8  0.8

.79

INR ( SD)

1.2  0.2

1.4  0.7

.94

1.2  0.24

1.2  0.4

.60

Prothombin time, s ( SD)

13.8  3.3

13.5  4.5

.69

13.8  3.3

13.2  4.9

.47

Underlying cirrhosis

33.8

30.8

< .001

33.8

31.5

.02

Esophageal varices

14.3

13.4

.11

14.3

13.7

.40

Hepatorenal syndrome

3.8

2.7

< .001

3.8

2.2

< .001

Steroid therapy

21.7

20.3

.04

21.7

21.0

.48

Course of illness, %

BMI, body mass index; COPD, chronic obstructive pulmonary disease; HbA1c, hemoglobin A1c; INR, international normalized ratio; SD, standard deviation.
a
Propensity matched analysis was performed and P < .05 was signiﬁcant.
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Supplementary Material
Data on TriNetX network were obtained from academic medical centers, specialty physician services, and
community hospitals. The data used is acquired from
TriNetX (https://www.trinetx.com/). TriNetX has
received a waiver from the institutional review board
because it does not contain any protected health information or the HCO Information. It only includes aggregated counts and statistical summaries of deidentiﬁed
information. Using TriNetX analytics platform, COVID-19
patients were identiﬁed based on Centers for Disease
Control and Prevention coding guidelines. Patients were
included if they had 1 or more of the following International Classiﬁcation of Diseases, Ninth and Tenth Revisions, Clinical Modiﬁcations (ICD-10-CM) codes in the
electronic medical records: U07.1 COVID-19; B34.2
coronavirus infection, unspeciﬁed; and B97.29 other
coronavirus as the cause of disease classiﬁed elsewhere.1
ICD-10 codes K74.60 (unspeciﬁed cirrhosis of liver),
K74.69 (other cirrhosis of liver), and K74.6 (other and
unspeciﬁed cirrhosis of liver) were included to identify
patients with cirrhosis of the liver. These COVID-19 patients with cirrhosis were divided into 2 groups: COVID19 patients without cirrhosis (group A), and COVID-19
with cirrhosis (group B). Comorbidities were identiﬁed
using codes I10 (essential hypertension), I20-25
(ischemic heart disease), N18 (chronic kidney disease),
E08-13 (diabetes mellitus), J44.9 (chronic obstructive
pulmonary disease, unspeciﬁed), and E65-E68 (overweight, obesity, and hyperalimentation).1,2 The data are
susceptible to coding or data entry errors when patient
information is translated into the ICD-10 codes. Only age
of death was available. Date of death is not available.
Underreporting of the data could be possible from HCO’s.
We could not report the inﬂuence of different HCOs
because of privacy restriction. Recording of ICD codes in
administrative data may vary in comorbidities, severity
of illness, length of hospitalization, and whether inhospital death occurred.3 However, the data collection
errors are minimized because TriNetx aggregates the
data directly from the electronic medical records.
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ICD 10 codes used:
Corona virus
U07.1, B34.2, B97.29, J12.81
Exclusion: B34.2, B97.2
Cirrhosis, Moon et al.4
K70.30, K70.31, K74.60, K74.69, K74.3, K74.4, K74.5
cirrhosis
Varices: I85.0, I 85.01, I85.10, I85.11, 86.4
Ascites: K70.31, K70.11, R18.8, K65.2
HE: K70.41, K72.11, K72.91, B15, B16, B17.11, B19.0,
B19.11, B19.21
HCC: C22.0, C22.8, C22.9
Cause of liver disease
K83.1 PSC
76.9 other speciﬁed diseases of liver
K76.89 other speciﬁed diseases of liver
K76.9 liver disease unspeciﬁed
K72.9 Hepatic failure
K71 Toxic liver disease
K75.81: NASH
K76.9 Fatty liver not elsewhere speciﬁed
B18 Chronic viral hepatitis
B19.1 unspeciﬁc viral hepatitis
K73. Chronic hepatitis not elsewhere classiﬁed
K75.3 Granulomatous hepatitis
K75.4 autoimmune hepatitis
K75.89 other speciﬁed inﬂammatory liver
disease
K76.81- HPS
K76.7- HRS
Other comorbidities
CV diseases ICD 10
I60-69
Substance abuse
F10-F19
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